Product Highlight - Forxiga
In DECLARE TIMI-58:
Forxiga has shown to provide early CARDIORENAL benefits beyond HbA1c reduction in T2DM patients across CV risks1,2,3
- Reduce the risk of hospitalization for heart failure compared to placebo by 27%.1
- Reduce the risk of progression to nephropathy compared to placebo by 47%.2^
- Well established safety profile compared to placebo.1,2
- Superior reduction of glycaemic control compared to DPP4i with additional benefit of weight loss and BP reduction.3,4*
^Forxiga is not indicated for the treatment of heart failure and chronic kidney disease.
* Forxiga is not indicated for the management of weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials. Blood pressure change was primarily assessed as a safety or exploratory endpoint.
1. Wiviott SD et.al. N Engl J Med. 2019; 380(4):347-357.
2. Mosenzon O et.al. The Lancet Diabetes & Endocrinology 2019 Aug 7(8):606-617.
3. Rosenstock J, et al. Presented at WCIRDC 2016 Poster 99.
4. Rosenstock J et.al. Arch Endocrinol Metab. 2018;62(4):424-430.